In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mederi CE marks second-gen Secca and Stretta systems

This article was originally published in Clinica

Executive Summary

Mederi Therapeutics has CE marked its second-generation Stretta and Secca systems for sale in Europe. Stretta, a therapy for gastroesophageal reflux disease, involves insertion of the Stretta catheter through the patient’s mouth and into the valve between the stomach and oesophagus. Radiofrequency energy is delivered to the lower oesophageal sphincter and gastric cardia to create small thermal lesions. When these lesions heal, the tissue contracts, narrowing the opening to the oesophagus and preventing reflux. The Secca system is designed to treat bowel control disorder, or BCD. It uses a similar technique to contract the anal sphincter. These latest versions of the systems have an improved interface, are easier to use, and are smaller, lighter, and highly portable, the Greenwich, Connecticut firm says.

You may also be interested in...

Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts